Clinical Trials Are Running Agentic AI Faster Than Regulators Can Define It
Agentic AI now handles protocol deviation detection and trial monitoring, but no current framework tests for decision drift across autonomous runs.
Find here all our blog posts tagged with: life-sciences.
When the Scientist Is an Agent: Governing AI Before It Reaches the IND
Ono Pharmaceutical's rollout of agentic AI to every discovery scientist exposes a governance gap that sits upstream of any device or wearable regulation.
Design Controls Weren't Built for Models That Change
FDA is piloting exceptions rather than rewriting design controls for GenAI devices, leaving compliance leaders to build the continuous verification the rule doesn't require.
Agentic AI in Clinical Trials Isn't Exempt From High-Risk Classification
Agentic AI tools for trial design look administrative, but EU AI Act and MDR overlap rules can pull them into conformity assessment regardless of vendor intent.
Three Regulators, Three Different Bets on AI Medtech
The EU, the US, and China are sequencing AI device oversight in opposite orders, and compliance leaders need to plan for all three.
The Change-Control Gap Between MDR and the AI Act
Predetermined change control plans reveal the specific reconciliation gap between MDR/IVDR certification and EU AI Act obligations for adaptive medical algorithms.
AI Clinical Decision Support Is Scaling Past Its Evidence
FDA clearance and predetermined change control plans govern AI software lifecycle, not clinical benefit, leaving hospitals to own the evidence gap.
Clinical Decision Support AI: Cleared, Not Proven
High-risk AI clinical decision support is scaling through FDA and IVDR pathways faster than its evidence base, leaving compliance leaders to close the gap regulators haven't.
Clearance Was Never the Finish Line
FDA's predetermined change control pathway shifts the real compliance burden from initial authorization to lifecycle governance of AI models after they ship.
Cleared Is Not Validated: The Evidence Gap Behind FDA's AI Device Count
FDA's public summaries for AI-enabled devices were built to demonstrate fairness, but their format makes that fairness nearly impossible to verify.
The Real AI Device Risk Is Where FDA Doesn't Look Closely
Most AI-enabled devices clear FDA through the least rigorous pathway or avoid device classification entirely, leaving agentic AI's failure modes unexamined.
AI Drug Discovery's Capital Boom Sits Outside the Regulatory Perimeter, Not Ahead of It
Discovery-stage AI funding is surging, but the mismatch compliance leaders should track is structural, not a simple case of regulation lagging money.
The Traceability Debt Building Inside AI-Native Drug Discovery
Closed-loop AI discovery platforms are compressing timelines faster than biopharma governance functions can build the audit trail regulators will eventually demand.
The Documentation Debt AI Drug Discovery Keeps Repeating
AI drug discovery's funding-to-approval gap echoes a governance failure regulators have already documented in medical devices, and the fix is the same.
AI Discovers Drugs. It Doesn't Approve Them.
AI drug discovery has drawn billions in investment but zero FDA approvals, and the bottleneck sponsors need to plan for is evidence, not speed.
The AI Drug Discovery Boom Is Outrunning Trial Execution
Generative AI is accelerating molecule design, but no AI-discovered drug has cleared trials, and regulators have yet to define how AI governs the trials themselves.
AI-Native Drug Discovery Needs Provenance Records, Not Just Speed
As generative AI moves into candidate generation and synthesis, sponsors must build data lineage and model audit trails before IND filing, not after.
AI Can Design a Drug. It Still Can't Get One Approved.
Generative AI is accelerating drug candidate design, but no AI-discovered molecule has reached approval because clinical trial execution and its regulatory footing remain unresolved.
AI Drug Discovery's Evidence Gap
Billions have flowed into AI drug discovery with zero FDA approvals, and the bottleneck is evidence infrastructure, not molecule generation.
The Trial Floor Is the Next Oversight Line, Not the Device Shelf
FDA's closed RFI on AI-enabled early-phase trials signals a second oversight track distinct from device review, and sponsors are moving faster than either.
The Convergence Gap in AI Life Sciences Regulation
Regulators describe AI, digital health, and clinical trial law as converging, but FDA, UK, and Chinese actions show the frameworks are still moving on separate, misaligned tracks.
When AI Guides the Hands, Not Just the Read
FDA's clearance of real-time ultrasound guidance AI creates a task-shifting risk category that standard imaging AI governance does not address.
FDA Is Assembling the Machinery Before It Finishes the Rule
FDA's device review architecture and new leadership roles point toward trial-side AI scrutiny, though the timeline and scope remain genuinely unsettled.
The Evidence Gap PV Automation Never Has to Close
FDA's mounting scrutiny of AI medical devices reveals evidence gaps even for cleared products, while pharmacovigilance AI faces no such test at all.
The Next Regulatory Question Isn't the Model. It's the Data It Rescued.
AI-driven reanalysis of failed clinical trials is producing new evidence outside the systems built to validate it, and GxP quality frameworks have not caught up.
The Doctor Test for AI Devices
FDA's move toward clinician-style, ongoing assessment of AI-enabled devices reshapes what counts as durable evidence, ahead of any final guidance.
When AI Guides the Scan, Governance Must Follow the Hands
FDA's clearance of real-time AI ultrasound guidance software shifts imaging AI governance from diagnostic accuracy to human-AI interaction validation.
The Trial Matching Black Box
Agentic AI that extracts and standardizes EHR data for oncology trial matching is becoming clinical trial infrastructure with no validation framework behind it.
When the Algorithm Is the Biomarker
Computational pathology AI blurs device and biomarker regulation, but predetermined change control plans, not model freezing, may be the real fix.
Ambient Voice AI Just Crossed the Medical Device Line
MHRA guidance on ambient voice technology signals that clinical AI scribes and voice assistants are now squarely inside medical device regulation, not adjacent to it.
The Oversight Question Autonomous Diagnostic AI Hasn't Answered
FDA's latest device clearances shift AI from assistive to autonomous interpretation, and compliance teams still lack a shared standard for human oversight.
Two New Fast Lanes for AI Devices, No New Evidence Standard
EU and FDA are both building faster pathways for AI medical devices, but neither has defined what evidence should earn a device the fast lane.
The Exemption Your CDS Tool Is Standing On Is Under Review
FDA's Section 3060 review of clinical decision support flexibilities means hospitals should stop assuming their AI-driven CDS tools sit outside device regulation.
AI Governance's Real Fault Line Is Classification, Not Geography
Divergence in AI rules across the US, EU, and China is driven less by geography than by conflicting definitions of what counts as a regulated AI function.
Device Clearance Outpaces Practice Governance
Tempus's third FDA-cleared AI-ECG tool shows the 510(k) pathway working smoothly, while new pharmacy guidance reveals governance gaps at the point of use.
Cleared, Qualified, Authorized: Three Different Promises
Regulated buyers are treating FDA clearance, institutional platform qualification, and De Novo authorization as interchangeable seals when they carry different evidentiary weight.
The Clinical AI Governance Gap Is Structural, Not Accidental
The regulatory perimeter around clinical AI is contested by design, and the same gap is opening upstream in drug development.
Clinical AI's Financial Case Is Made. Its Audit Trail Isn't.
Drug discovery and trial AI are proving their financial return faster than sponsors are building the validation records to defend that work at inspection.
The Clinical Trial Has No AI Rulebook
Sponsors are deploying AI across trial execution with no dedicated regulatory framework, leaving GCP and data integrity obligations to fill the gap alone.
The MedTech Compliance Asset Has a Shelf Life
MedTech buyers are pricing compliance documentation as a deal asset, but the standards that file is graded against are still being written.
HealthTech Buyers Are Pricing Compliance Before the Rules Agree With Each Other
Diligence teams valuing AI-enabled health devices are treating EU AI Act readiness as a settled asset, but FDA, EU, and China are still diverging on what that documentation must show.
The Continuous-Update Trap in Medical AI Governance
FDA now lets manufacturers update AI devices without new submissions, but EU's MDR/IVDR and AI Act stack offers no equivalent, forcing a split lifecycle strategy.
The Decoupled Diagnostic: Who Owns the Scan
FDA's clearance of AI that lets non-specialists capture diagnostic scans creates a workflow no existing device framework was built to assign liability for.
Design Controls Were Built for Outputs, Not Agentic Reasoning
FDA's total product life cycle framework for AI-enabled devices documents data lineage and output correctness, but not the intermediate process failures unique to agentic architectures.
EMA Moved First on AI. FDA Is Still Deciding How.
EMA's lifecycle-wide AI reflection paper and FDA's still-open genAI device rulemaking are running on different clocks, and neither is finished business for regulated buyers.
The EU AI Act Extension Is Not the Relief It Looks Like
Brussels pushed back the high-risk AI Act deadline for regulated medical devices, but MDR and IVDR certification bottlenecks did not move with it.
The EU AI Act Extension Is a Delay, Not a Reprieve
The Digital Omnibus pushes the EU AI Act high-risk deadline for medical devices to August 2027, but MDR/IVDR and EMA already require the same work now.
Europe's AI Act and MDR Collide, and MedTech Wants a Rewrite
European MedTech is lobbying to revise how the EU AI Act and MDR/IVDR interact, and regulated buyers should build to the stricter combination now, not wait for the fix.
Europe's AI Act and MDR Are Being Rewritten at the Same Time
European regulators are revising the AI Act and MDR simultaneously, leaving life sciences compliance teams no stable baseline to build against.
The Extended Clock Is Not a Reprieve
The EU AI Act's delayed enforcement dates for medical device AI give sponsors more runway, but only if they use it to align MDR/IVDR and AI Act evidence now.
The EU AI Act Grace Period Is a Countdown, Not a Pause
Brussels pushed high-risk AI enforcement for medical devices to 2027 and 2028, but the multi-year MDR/IVDR build-out clock is already running.
The EU AI Act Reprieve Is a Timing Bet, Not a Pause
Digital Omnibus alignment gives AI-enabled medical devices breathing room on paper, but MDR/IVDR certification obligations have not moved and neither has the underlying risk.
Life Sciences Is Merging Two EU AI Act Obligations Into One
EU AI Act transparency rules for content marking and interaction disclosure are distinct obligations, and life sciences compliance teams keep treating them as one.
Europe's New Fast Lane for Breakthrough AI Devices Comes With No Governance Shortcut
The EU's new Breakthrough Devices framework under MDR/IVDR speeds review timelines but leaves AI governance obligations fully intact.
Capital Is Flowing to AI. Regulatory Science Capacity Is Not.
EU device rules, FDA benchmarking, and pharma's AI rollout share one constraint: regulators lack the evidence infrastructure to keep pace with deployment.
The Qualification Test That Redraws the AI Device Line
A new EU Court judgment on medical device qualification means AI tools built as informational or decision-support software may already sit inside MDR and IVDR scope.
Europe's Dual Certification Trap for Clinical AI
AI systems that influence clinical decisions can trigger MDR and EU AI Act obligations at once, and the Digital Omnibus timeline does not change that exposure.
The Non-Device Trap in EU Pharma AI
US pharma AI tools that avoid MDR device classification still face full exposure under the EU AI Act, GDPR, and EHDS.
The Evidence Gap Behind AI Clinical Decision Support
AI decision support tools are scaling into hospitals faster than the evidence and oversight infrastructure needed to trust them.
FDA's Postmarket AI Machinery Is Still Under Construction
Recent FDA moves on AI-enabled devices signal a postmarket framework taking shape, but the agency's own uncertainty argues against treating early engagement as a settled strategy.
The Readiness Gap Behind FDA's 1,000 AI Devices
FDA's large base of authorized AI-enabled devices masks a readiness gap that generative and agentic systems will expose immediately.
The Governance Gap Behind FDA's AI Device Surge
FDA's AI-enabled device authorizations are scaling faster than lifecycle governance infrastructure, and the same gap is now stalling AI drug discovery approvals.
FDA's AI Perimeter Is Widening and Narrowing at the Same Time
FDA is loosening wellness device classification while tightening AI change control mechanics, and the gap between the two is where compliance risk now sits.
When the Regulator's Capacity Becomes Your Risk
FDA's shrinking resourcing and the MDUFA VI negotiations mean AI device sponsors can no longer treat PCCP approval as the end of verification.
The Real Gap Isn't Evidence. It's Framework Fit.
AI medical device clearances are outpacing the regulatory architecture meant to govern them, and hospitals are deploying generative AI ahead of any classification at all.
FDA Clearance Is Not the Evidence Trail
FDA-authorized AI devices are outpacing the evidence behind their safety and equity claims, leaving health systems to build the diligence layer themselves.
FDA's Other AI Track: Drug Development Gets Its Own Playbook
While FDA's device guidance draws attention, a parallel track for AI in early-phase clinical trials and drug development is quietly taking shape.
Static Categories, Adaptive Systems: The Real Fault Line in AI Device Review
FDA and EU sandbox pilots for agentic AI are one symptom of a broader breakdown in static regulatory categories, and buyers should treat both the hype and the early-engagement tradeoffs with equal scrutiny.
The FDA-EU Fork in AI-Enabled Medical Devices
FDA is building adaptive, lifecycle-based pathways for AI-enabled devices while the EU stacks AI Act obligations atop MDR and IVDR, forcing a sequencing decision now.
FDA's GenAI Framework Is Still a Draft of a Draft. That's the Opportunity.
FDA's two-axis risk framework for generative AI medical devices is not policy yet, and the October 19 comment window is the cheapest chance to shape it before it hardens.
The Comment Window That Will Define GenAI Medical Devices
FDA's open docket on generative AI medical devices is the narrow window life sciences leaders have to shape binding rules before they harden.
FDA's GenAI Guidance Gap Puts Lifecycle Design on the Critical Path
FDA is still soliciting input on generative AI device oversight while conventional AI/ML tools keep clearing through 510(k), forcing sponsors to design lifecycle monitoring ahead of guidance.
FDA's Discussion Paper Moves the Goalposts on GenAI Devices
FDA's generative AI discussion paper signals a shift from one-time approval to continuous, competency-based testing that life sciences compliance teams should prepare for now.
The FDA Is Still Asking Questions. Brussels Already Moved Its Clock Once.
FDA's open genAI comment period and the EU's already-shifted AI Act deadlines argue for building the shared lifecycle core, not betting on either jurisdiction's paperwork.
FDA's GenAI Pilot Is Ahead of Its Own Guardrails
FDA's provisional pathway for generative AI devices exposes a verification gap that output benchmarks and existing life cycle rules were not built to close.
The FDA's Open Docket Is the Real Deadline
FDA's move toward assessing generative AI devices like clinicians raises real feasibility questions, but sponsors who wait for guidance will lose the argument.
FDA's Lifecycle Bet on GenAI-Enabled Devices
FDA is easing premarket friction for AI-enabled devices while shifting the real compliance burden to post-market monitoring that current guidance cannot yet catch.
PCCP Is Settled. The Benchmarks Underneath It Are Not.
FDA's change control pathway for AI-enabled devices is mature, but the benchmarking standards sponsors need to use it well are still unresolved.
The Benchmark Gap Inside FDA's AI Change Control Plans
FDA's Predetermined Change Control Plan guidance lets AI devices update without new submissions, but no validated benchmarking standard tells manufacturers where drift becomes risk.
Health AI Is Straining Categories, Not Just Rules
US data provenance, UK product classification, and Chinese jurisdictional scope are all cracking under AI health tools that don't fit pre-AI regulatory taxonomy.
Routine Health Data Is Fueling AI Devices Faster Than FDA Can Define the Standard
FDA's December 2025 real-world evidence guidance lets sponsors train AI devices on routine health data, but provenance and bias standards remain undefined.
FDA's New Deputy Commissioner Post Is the Real AI Signal
HHS is creating a dedicated technology leadership role at FDA, and that appointment will shape AI device oversight more than any single guidance document.
What FDA's Tempo Pilot Actually Asks Compliance Leaders to Decide
FDA's reported Tempo pilot lets generative AI devices reach patients ahead of authorization, and the public record on how is thinner than the headline suggests.
The Blind Spot Beneath FDA's Generative AI Test
FDA's two-axis approach to generative AI devices is a familiar SaMD extension, but existing inspection data suggest most manufacturers can't yet clear the bar it sets.
FDA's Three-Part Test for Agentic Devices
FDA's generative AI discussion paper outlines a safety, proficiency, and generalizability framework that will shape validation evidence long before formal guidance arrives.
The Generative AI Gap in FDA's Device Playbook
FDA has cleared over 1,000 AI-enabled devices, but generative AI features still lack a defined regulatory pathway, forcing sponsors to choose their architecture carefully.
In HealthTech M&A, AI Governance Is Now a Line Item on the Term Sheet
Buyers in HealthTech and MedTech deals are pricing AI governance maturity directly into valuation, not treating it as a closing condition.
The Governance Debt Building in Drug Discovery AI
Regulatory frameworks are expanding toward AI in drug development, but the real exposure is a silent-failure risk that neither hype skeptics nor regulators are pricing in yet.
The Governance Gap Belongs to the Deployer, Not the Regulator
Hospitals and pharma functions adopting generative AI now carry governance obligations that device and drug frameworks were never built to cover.
One Journal Article Is Not Yet an AI Audit Standard
A single peer-reviewed framework is being framed as the working audit standard for generative AI mental health tools, and compliance leads should treat that framing with more caution than the coverage suggests.
Three Regulators, Three Clocks, One AI-Enabled Device
The EU, US, and China are each running statute ahead of certification infrastructure for AI-enabled medical devices, and manufacturers need one documentation architecture, not three.
MedTech Diligence Now Has to Read Change Plans, Not Just Technical Files
AI-enabled devices are adding predetermined change control plans to MDR/IVDR technical files, and buyers evaluating MedTech targets need to diligence both.
MDUFA VI Is a Capacity Signal, Not the Whole Story
The MDUFA VI negotiation matters for AI device review capacity, but sponsors treating it as the sole variable are missing parallel forces already shaping their timelines.
The Benchmarking Gap FDA Hasn't Closed
Nature Medicine's new framework for evaluating generalist medical AI outpaces FDA's device-modification tools, leaving capability-tier governance to buyers.
A Journal Article Is Not a Regulatory Safe Harbor
A Nature Medicine audit framework for AI mental health tools is being framed as a de facto FDA standard, but no published mechanism makes that so.
The AI Lifecycle Decision Medtech Can't Wait to Make
J&J's Monarch clearance shows predetermined change control plans already govern AI updates, a lifecycle discipline device makers need now, not after genAI guidance lands.
Your Patients Are Uploading Health Data Into a Regulatory Gap
Life sciences firms building patient-facing AI tools are relying on a HIPAA and FDA perimeter that consumer health AI routinely sits outside.
The PCCP Illusion: Why US Speed Doesn't Buy EU Clearance
FDA's finalized change control pathway lets AI devices update without new submissions, but the EU AI Act demands continuous oversight that PCCPs were not built to satisfy.
The PCCP Gap: FDA Lets AI Models Change, Europe Asks Which Model You Meant
FDA's finalized change control plans let AI-enabled devices update without new submissions, but EU classification law may treat the same update as a new device.
The PCCP's Global Convergence Is a Hypothesis, Not Yet a Standard
IMDRF has laid out principles for regulators to adopt predetermined change control plans, but FDA and the EU's MDR/IVDR regime remain far from aligned.
The PCCP Is the Real Clearance
FDA's predetermined change control plans, not the original device clearance, now define how far an AI-enabled medical device can drift without new review.
Generative AI Isn't Breaking Device Rules. It's Avoiding Them.
FDA's generative AI vacuum in clinical SaMD is pushing vendor activity toward drug discovery applications that sit outside device regulation entirely.
The PCCP Is the Real Decision, Not the Generative AI Docket
FDA's Predetermined Change Control Plan guidance, not the open generative AI docket, is the mechanism sponsors must decide on now for AI-enabled devices.
The Clearance Isn't the Risk. The Change Control Plan Is.
As high-risk AI medical devices scale, the decisive diligence question shifts from FDA clearance status to what a manufacturer's change control plan permits it to alter unsupervised.
The PCCP Window Before the AI Act Deadline Closes
IMDRF's new PCCP principles and the EU AI Act's delayed medtech deadline create a narrow window to build one change control architecture instead of two.
Pharma's AI Pipeline Is Running on Two Regulatory Clocks
Drug discovery AI is accelerating faster than either the EU AI Act or FDA's generative AI framework can stabilize, forcing pharma to classify now or re-litigate later.
The Architecture Decision Pharmacovigilance AI Cannot Defer
Cross-jurisdictional data rules are forcing pharma safety teams to choose between centralized and localized AI architectures before regulators force the choice for them.
Quantum-Classical AI Enters Drug Discovery, Validation Frameworks Don't
Quantum-enhanced generative AI is moving into drug discovery pipelines faster than GxP validation and data integrity practices can absorb it.
The Guidance Cannot Outrun the Model
FDA and EU regulators are structurally too slow to govern AI at the pace it changes, so life sciences compliance leaders must build internal governance now.
FDA's RWE Guidance Widens the Door. It Doesn't Lower the Bar.
FDA's final real-world evidence guidance broadens what device sponsors can submit, but the decision that matters is whether data pipelines can meet the traceability bar the broader door implies.
FDA Loosens the Data Bar. The EU Hasn't Said It Will Follow.
FDA's new real-world evidence flexibility for AI devices creates a sequencing risk for manufacturers still reconciling MDR/IVDR and EU AI Act data governance demands.
The Quality System Nobody Rebuilt Yet
FDA's living PCCP model for AI-enabled devices demands continuous evidence trails that most design control systems were never built to produce.
The Platform Risk Hiding in Serial Clearances
Tempus AI's third ECG-based FDA clearance shows how one platform can accrete indications faster than buyers can verify its cumulative risk profile.
The Governance Gap FDA's Rulemaking Won't Reach
FDA is still asking questions about generative AI in medicine while health systems already run it inside clinical workflows unmonitored.
Simulation-Guided Trials Are Ahead of the Law
Digital twins and virtual control arms are entering pivotal trial design faster than GDPR and MDR frameworks can validate the data behind them.
Surgical AI's Classification Is a Bet, Not a Badge
Medtronic's Aide platform is cleared as a low-risk data system, but AI-assisted surgery is moving toward active guidance faster than that classification can hold.
The Money Is Ahead of the Rulebook in Trial AI
Capital is flooding into AI for clinical trial conduct while regulators have yet to define what governs it, leaving sponsors exposed.
The Governance Gap in Clinical Trial Operations AI
Agentic AI is spreading through trial enrollment, monitoring, and feasibility work faster than FDA, EU AI Act, or ISO 42001 pathways built for medical devices can reach it.
Life Sciences AI Is Moving at Two Different Speeds
Diagnostic AI is clearing FDA review on schedule while AI-native drug discovery still has zero approvals, and the gap is documentation, not science.
Two Speeds of FDA AI Clearance
The FDA's bounded-diagnostic clearances and its generative-AI comment period reveal a widening split in medical AI oversight that regulated buyers must plan around now.
The New Fault Line: When Identical Hardware Faces Opposite FDA Rules
FDA's finalized wearable guidance means device classification now hinges on claims and labeling, turning product marketing into a regulatory control point.
When Health Data Leaves the Regulated Perimeter
FDA's wellness classification determines more than marketing claims. It decides whether patient data uploaded to AI tools carries any regulatory protection at all.
